Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification
Reexamination Certificate
2007-12-11
2007-12-11
Weber, Jon (Department: 1656)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
C435S069100, C435S004000, C530S350000
Reexamination Certificate
active
10969335
ABSTRACT:
The application identifies fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
REFERENCES:
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 6780971 (2004-08-01), Wolozin et al.
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 2004/041067 (2004-05-01), None
Bennett et al., “Degradatiuon of α-Synuclein by Proteasome*,”J. Biol. Chem., 274:33855-33858 (1999).
Crowther et al., “Synthetic filaments assembled from C-terminally truncated a-synuclein,”FEBS Letters, 436:309-312 (1998).
Ellis et al., “α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases,”J. Biol. Chem., 276(6):3879-3884 (2001).
Giasson et al., “Mutant and Wild Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro,”J. Biol. Chem., 274(12):7619-7622 (1999).
Kim et al., “Structural and functional implications of C-terminal regions of alpha-synuclein,”Biochemistry, 41(46):13782-13790 (2002).
Lee et al., “Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors*,”J. Biol. Chem., 277(7):5411-5417 (2002).
Mishizen-Eberz et al., “Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro,”J. Neurochemistry, 86(4):836-847 (2003).
Watson et al., “The Introduction of Foreign Genes into Mice,”Molecular Biology of Watson Recombinant DNAs, 2nd edition, pp. 255-272 (1993).
Hamburger et al., “Isolation and characterization of monoclonal antibodies reactive with endothelial cells,”Tissue Cell, 17(4):451-459 (1985) abstract only.
Hoyer et al., “Dependence of alpha-Synuclein Aggregate Morphology on Solution Conditions,”J. Mol. Biol., 322:383-393 (2002).
Kim et al., “Structural Change in Alpha-Synuclein Affect its Chaperone-like Activity In Vitro,”Protein Science, 9:2489-2496 (2000).
Okochi et al., “Constitutive Phosphorylation of the Parkinson's Disease Associated alpha-Synuclein,”J. Biol. Chem., 275(1):390-397 (2000).
Takahashi et al., “Phosphorylation of α-synuclein characteristic of synucleinopathy lesions in recapitulated in α-synuclein transgenicDrosophila,”Neuroscience Letters, 336:156-158 (2003).
Tsim et al., “Monoclonal antibodies specific for the different subunits of asymmetric acetylcholinesterase from chick muscle,”J. Neurochem., 51(1):95-104 (1988) abstract only.
Anderson et al., “Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease,”J. Biol. Chem., 281(40):29739-29752 (2006).
Crowthier et al., “Synthetic filaments assembled from C-terminally truncated α-synuclein,”FEBS Letters, 436:309-312 (1998).
Li et al., “Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations,”PNAS, 102(6):2162-2167 (2005).
Liu et al., “A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation,”J. Biol. Chem., 280(24):22670-22678 (2005).
Miake et al., “Biochemical Characterization of the Core Structure of α-synuclein Filaments,”J. Biol. Chem., 277(21):19213-19219 (2002).
Mishizen-Eberz et al., “Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro,”J. Neurochemistry, 86:836-847 (2003).
Murray et al., “Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro,”Biochemistry, 42:8530-8540 (2003).
Serpell et al., “Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation.,”PNAS, 97(9):4897-4902 (2000).
Anderson John P
Chilcote Tamie J
Gai Wei Ping
Goldstein Jason
Elan Pharmaceuticals Inc.
Mitra Rita
The Trustees of Flinders University
Townsend and Townsend / and Crew LLP
Weber Jon
LandOfFree
Truncated fragments of alpha-synuclein in Lewy body disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated fragments of alpha-synuclein in Lewy body disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated fragments of alpha-synuclein in Lewy body disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878408